Loma Linda Oncology Medical Group Inc, Claremont, CA 91711, USA.
Cancer Invest. 2010 Oct;28(8):833-8. doi: 10.3109/07357901003630942.
We conducted a phase I trial of chemotherapy in patients with advanced gastro-esophageal cancer.
Eligible patients had chemotherapy doses increased until dose limiting toxicity (DLT) was observed.
Fourteen patients were accrued. No DLT was observed in first three patients at level 1. DLT was observed in two out of five patients at level 2. Six additional patients were treated at level 1.
Recommended doses for future trials are: docetaxel 30 mg/m(2) and oxaliplatin 50 mg/m(2) on days 1 and 8 and capecitabine 675 mg/m(2) PO, bid, on days 1-14 on a three weekly basis.
我们对晚期胃食管癌症患者进行了化疗的 I 期临床试验。
符合条件的患者接受递增化疗剂量治疗，直至出现剂量限制性毒性（DLT）。
共入组 14 例患者。在 1 级治疗的前 3 例患者中未观察到 DLT。在 2 级治疗的 5 例患者中观察到 2 例 DLT。6 例额外患者在 1 级治疗。
推荐用于未来试验的剂量为：多西紫杉醇 30mg/m²，奥沙利铂 50mg/m²，第 1 和第 8 天静脉滴注，卡培他滨 675mg/m²，口服，bid，第 1-14 天，每 3 周一次。
